# INTELECTUAL PROPERTY IMPORTANCE IN EXAMPLE OF RECENT PATENTS IN THE FIELD OF BIOMATERIALS

Dragana T. Živković<sup>1</sup>, Milica Lj. Niculović<sup>1</sup>, Ljubiša T. Balanović<sup>1</sup>, Dragan M. Manasijević<sup>1</sup>, Vladan R. Ćosović<sup>2</sup>, Nadežda M. Talijan<sup>2</sup>, Ivana P. Janković<sup>3</sup>

<sup>1</sup> University of Belgrade, Technical Faculty in Bor, VJ 12, Bor, Serbia
<sup>2</sup> University of Belgrade, Institute of Chemistry, Technology and Metallurgy, Njegoševa 12, Belgrade, Serbia
<sup>3</sup> Health Center, Zaječar, Serbia

## ABSTRACT

The number of patents has been increasing steadily nowadays, forcing companies to consider intellectual property as a part of their strategy. Patent analysis and patent mapping are used as effective tools to quickly view a portfolio of patents.

The analysis of patents, as important significations of intellectual property in the field of biomaterials, was done using specific database - the International Patent Classification and Patent Scope - for the period 2003 to 2013 and obtained results are presented in this paper. **Keywords:** Biomaterials, Patent analysis, Patent databases.

### **1. INTRODUCTION**

With the evolution of human civilization, the field of biomaterials evolved involving different materials at multiple length scales from macro to micro and to nano level with a simple focus to extend human life and improve the quality of life [1].

A biomaterial can be defined as any material used to make devices to replace a part or a function of the body in a safe, reliable, economic, and physiologically acceptable manner [2].

Materials can be classified into different groups based on crystal structure, bonding, and macrostructures, showing somewhat similar properties. The most common classes of materials used as biomaterials are metals, polymers, ceramics, and composites [1, 3]. Specific metallic biomaterials can be made from stainless steels, alloys of cobalt, titanium and magnesium, as well as shape memory alloys of nickel-titanium, silver, tantalum and zirconium [4].

Interest in biomaterials research has been growing in the last decade, as a life-saving and lifeimproving option for countless patients, so biomaterials have been paid more and more attention. They has been developed as a science with various forms of implants/medical devices, widely used to replace and/or restore the function of traumatized or degenerated tissues or organs [5].

Current research interest focuses principally on tissue engineering, prostheses, bone regeneration, biological materials, drug delivery/nanoparticles, implants / surgery tools, methods and processes / sensors / diagnosis tools, surface modification / coatings, artificial tissues / organs, bio adhesives [6, 7].

When considering a biomaterial for implantation or medical use, the first most important requirement is non-toxic, non-immunogenic, chemically inert/active, and acceptable by the human body. Biocompatible in most cases means that the biomaterials must not form thrombi in the blood system, result in tumors in the surround tissues, or rejected by the body [5]. Critical issues in their clinical applications are systemic toxicity of released metal ions due to corrosion, fatigue failure of structural components due to movement [4].

## 2. METHODOLOGY

Although a large number of patents are technically significant, only a few patents actually develop into something of commercial value [8]. In order to gain an insight to an overall technology forecasting model, it is important to understand the growth in an area of technology and to measure using keywords or phrases [9]. Both scientific journals and patent databases record a high increase in publications in biomaterials area [5, 10]. Patent analysis represents a "valuable approach that uses patent data to derive information about a particular industry or technology used in forecasting" [9].

The objective of this work was to give an overview of current situation of biomaterials based on patent analysis for the period from the year 2003 to 2013. The analysis was done using the International Patent Classification and Patent Scope [10]. This database provides a lot of information about patents which helped to complete this analysis successfully. Information found in this database was about number of patents, patent classification by country, patent applicators, main inventors and pub date.

## **3. RESULTS AND DISCUSSION**

According to the results obtained using the International Patent Classification and Patent Scope, there were 42.661 patents within the field of biomaterials (Figure 1.) in period from the year 2003 to 2013. Following pictures demonstrate lists of countries where patents were registered, applicators, inventors and the year of registration.

23267	A61K	15959	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA MASSACHUSETTS INSTITUTE OF TECHNOLOGY	244 204	BEVEC, Dorian	146	2003	2239
13425	A61L	9434			Hunter William L.	123	2004	2327
4320	A61F 8	8689			Sung Hsing-Wen	90	2005	2705
	C12N	6329	Massachusetts Institute of	171	VANANGAMUDI,	67	2006	2946
433	A61P	4861	Technology		Sulur, Subramaniam		2007	3203
314	A61B	4217	The Regents of the University	149	Brister Mark	53	2008	3639
228	COTK	4131	of California		Bevec Dorian	48	2009	3807
218	0041	2004	NOVARTIS AG	142	Mirkin Chad A.	47	2009	4050
178	GUIN	3884	Medtronic, Inc.	134	Hubbell Jeffrey A	42	2010	4056
	C08G	2177	MONDOBIOTECH	131			2011	3969
163	C12Q	2146	LABORATORIES AG	131	Relley Mark A.	41	2012	3432
58			BOSTON SCIENTIFIC	120	Kohn Joachim B.	38	2013	2534
			SCIMED, INC.					
26			DexCom, Inc.	111				
			ALLERGAN, INC.	97				
12								
12								
5								
	23267 13425 4320 433 314 228 218 178 163 58 26 12 12 12 5	23267 A61K A61K A61L A61F C12N A61P A61B C07K G01N C08G C12Q C12Q C12Q C12Q C12Q	23267         A61K         15959           13425         A61L         9434           4320         A61F         8689           433         A61P         4329           434         A61P         4861           314         A61B         4217           228         C07K         4131           218         G01N         3994           178         C12Q         2146           58         26         12           12         5         12	23267         A61K         15959           13425         A61L         9434           4320         A61F         8689           C12N         6329           A61B         4217           C07K         4131           G01N         3994           C12Q         2146           S8         BOSTON SCIENTIFIC           26         SCIMED, INC.           12         ALLERGAN, INC.	23267         A61K         15959         THE REGENTS OF THE UNIVERSITY OF CALIFORNIA         244           13425         A61L         9434         MASSACHUSETTS INSTITUTE OF TECHNOLOGY         204           4320         A61F         8689         MASSACHUSETTS INSTITUTE OF TECHNOLOGY         204           433         A61P         4861         Massachusetts Institute of Technology         171           218         G01N         3994         The Regents of the University of California         142           163         C12Q         2146         MoNORATIS AG         142           163         C12Q         2146         BOSTON SCIENTIFIC         120           28         SCIMED, INC.         DexCom, Inc.         111           12         ALLERGAN, INC.         97	23267     A61K     15959     THE REGENTS OF THE UNIVERSITY OF CALIFORNIA     244     BEVEC, Dorian       13425     A61L     9434     MASSACHUSETTS INSTITUTE OF TECHNOLOGY     204     Hunter William L.       433     A61F     8689     Massachusetts Institute of Technology     171     Surg Hsing-Wen       433     A61B     4217     The Regents of the University of California     171     Surg Hsing-Wen       228     C07K     4131     NOVARTIS AG     149     Brister Mark       218     G01N     3994     NOVARTIS AG     142       163     C12Q     2146     Medtronic, Inc.     134       163     C12Q     2146     BOSTON SCIENTIFIC SCIMED, INC.     120       26     DexCom, Inc.     111     ALLERGAN, INC.     97	23267         A61K         15959         THE REGENTS OF THE UNIVERSITY OF CALIFORNIA         244         BEVEC, Dorian         146           13425         A61L         9434         MASSACHUSETTS INSTITUTE OF TECHNOLOGY         204         Hunter William L.         123           4320         A61F         8689         OF TECHNOLOGY         204         Sung Hsing-Wen         90           433         A61P         4861         Massachusetts Institute of Technology         171         Sung Hsing-Wen         90           433         A61B         4217         The Regents of the University of California         149         Brister Mark         53           208         207K         4131         NOVARTIS AG         142         Mirkin Chad A.         47           178         G01N         3994         ModopatoTeCH LABORATORIES AG         131         Mirkin Chad A.         41           163         SS         SCIMED, INC.         120         SS         DexCom, Inc.         111           12         S         DexCom, Inc.         111         ALLERGAN, INC.         97	23267         A61K         15959         THE REGENTS OF THE UNIVERSITY OF CALIFORNIA         244         BEVEC, Dorian         146         2003           13425         A61L         9434         MASSACHUSETTS INSTITUTE         204         Sung Hsing-Wen         90         2005           433         A61P         4631         Massachusetts Institute of Technology         171         Sung Hsing-Wen         90         2006           433         A61B         4217         The Regents of the University of California         149         8evec Dorian         48         2009           218         G01N         3994         Modrationic, Inc.         134         Mirkin Chad A.         47         2010           163         C12Q         2146         MONORATORIES AG         142         Mirkin Chad A.         47         2012           58         C12Q         2146         BOSTON SCIENTIFIC         120         2013         2013           12         DexCom, Inc.         111         ALLERGAN, INC.         97         97         2013

Figure 1. Summary data of biomaterials patents, Source: International Patent Classification (Patent Scope)



Figure 2. Review of biomaterials patents per countries, Source: International Patent Classification (Patent Scope)

As presented in Figure 2. United States has considerable advantage over countries which have most registered patents - from a total of 42.661 registered patents even 23.267 patents (about 55% of total). In analysed period from the year 2003 to 2013, main applicators for biomaterials patents (Figure 3.) were the Regents of the University of California (244 applications).

According to Figure 4, Bevec Dorian (143 patents) and Hunter William (123 patents) were the inventors with most registered patents, whereas most of biomaterials patents (Fig. 5.) were registered in the years 2010 (4056 patents) and 2011 (3969 patents).



Figure 3. Review of main applicants for biomaterials patents, Source: International Patent Classification (Patent Scope)



Figure 4. Review of main inventors for biomaterials patents, Source: International Patent Classification (Patent Scope)



Figure 5. Review of pub date for biomaterials patents, Source: International Patent Classification (Patent Scope)

"Materials intended for biomedical purposes have evolved through three different generations, namely first generation (bioinert materials), second generation (bioactive and biodegradable materials) and third generation (materials designed to stimulate specific responses at the molecular level)" [11].

More than ten years of research and development of new biomaterials resulted in extending number of patents such as medical devices, implants and prostheses. Therefore, the presented results show that there is a growth of registered patents in general. This can be explained with the fact that biomaterials can be used for medical purposes and their acceptability by the human body [3]. The development and use of biomaterials is expected to dramatically increase over the coming decades as a result of ageing populations in Europe, China, Japan and the USA [12]. In the United States, the country with most registered patents, there are more than 13 million implant/medical devices implanted annually [5]. From 1997 until 2007 the European Union (EU) has funded biomaterials research projects (RTD) under its Fifth and Sixth Framework Programmes - 38 biomaterials projects were funded, with a total granted amount of  $\in 66.6$  million and research interest focused principally on tissue engineering, bone repair, diagnostic tools and medical adhesives [7]. Even though the Global Financial Crises in 2010 brought to a slight fall in registration of biomaterials patents, biomaterials for health will become a major focus of European research efforts in the coming years and as part of the Horizon 2020 Framework Programme for Research and Innovation [13].

#### 4. CONCLUSION

The analysis of patents, as important significations of intellectual property in the field of biomaterials, was done with specific database, using the International Patent Classification and Patent Scope for the period 2003 to 2013 and presented in this paper. It has been showed that the number of registered patents in the field of biomaterials was growing from year to year, and that United States is the country with the most registered patents. This drastic increase in number of announced patents can be explained by the fact that there was a significant investment in biomaterials research and development in the past ten years with the exception of Global Financial Crises in 2010. In accordance with previous facts, presented patent analysis in the field of biomaterials may be useful for trend monitoring in this scientific and technological field, being of interest for further technological forecasting and management.

#### Acknowledgement

The authors of this paper are grateful to the Ministry of Education, Science and Technological Development of the Republic of Serbia for financial support under the project OI 172037.

#### **5. REFERENCES**

- [1] Bose S, Bandyopadhyay A. Introduction to Biomaterials. Characterization of Biomaterials. 2013:1-9.
- [2] Park J, Lakes RS. Biomaterials: An introduction. Third edition ed: Springer-Verlag New York; 2007. 1-561 p.
- [3] Patel N, Gohil P. A Review on Biomaterials: Scope, Applications & Human Anatomy Significance. International Journal of Emerging Technology and Advanced Engineering. 2012;2(4):91-101.
- [4] Chen Q, Thouas GA. Metallic implant biomaterials. Materials Science and Engineering R: Reports. 2015;87:1-57.
- [5] Xiaohong W. Overview on Biocompatibilities of Implantable Biomaterials In: Pignatello R, editor. Advances in Biomaterials Science and Biomedical Applications 2013.
- [6] Tathe A, Ghodke M, Nikalje AP. A brief review: Biomaterials and their application. International Journal of Pharmacy and Pharmaceutical Sciences. 2010;2(4):19-23.
- [7] European Commission http://ec.europa.eu/research/industrial\_technologies/pdf/biomaterials-forhealthcare-web\_en.pdf.
- [8] Ashton WB, Sen RK. Using patent information in technology business planning-II. Research Technology Management. 1989;32(1):36-42.
- [9] Daim TU, Rueda G, Martin H, Gerdsri P. Forecasting emerging technologies: Use of bibliometrics and patent analysis. Technological Forecasting and Social Change. 2006;73(8):981-1012.
- [10] Patentscope. https://patentscope.wipo.int. [cited 2015 10 May].
- [11] Biomaterials, Market. Global Forecasts to 2017, Healthcare Consulting MarketsandMarkets 2013.
- [12] Narayan RJ. The next generation of biomaterial development. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences. 2010;368(1917):1831-7.
- [13] Donnelly F. European perspectives on biomaterials for health. EWMA Journal. 2015;15(1):54-8.